SynthesisJournal of the renin-angiotensin-aldosterone system : JRAAS
No association of adiponectin +45 T/G polymorphism with the risk of gestational diabetes mellitus: Evidence from a meta-analysis.
Synthesis in Journal of the renin-angiotensin-aldosterone system : JRAAS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-omics integration analysis and association study reveal the potential of ADIPOQ function in gestational diabetes mellitus.Nutrition & diabetes · 2025Article
- ADIPOQ gene (T45G and G276T) single nucleotide polymorphisms and their association with gestational diabetes mellitus in a Filipino population.BMC endocrine disorders · 2023Article
- Pathophysiological Role of Genetic Factors Associated With Gestational Diabetes Mellitus.Frontiers in physiology · 2022Review
- Adiponectin gene polymorphisms and risk of gestational diabetes mellitus: A meta-analysis.World journal of clinical cases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdiponectin (ADIPOQ), involved in regulating glucose levels and fatty acid oxidation, plays key roles in metabolic derangements such as gestational diabetes mellitus (GDM). Previously, several studies have been conducted to assess the association between ADIPOQ +45 T/G polymorphism and risk of GDM. The results, however, are inconclusive. We aimed to evaluate the effect of the polymorphism on the risk of GDM using a meta-analysis. MATERIALS AND
methodsAfter databases searching, eight records were identified. Pooled odds ratios (ORs) with their corresponding 95% confidence intervals (CIs) were used to evaluate the association between ADIPOQ +45 T/G polymorphism and risk of GDM.
resultsNo significant association was observed between the ADIPOQ +45 T/G polymorphism and the risk of GDM (heterozygote comparison: OR = 1.15, 95% CI, 0.70-1.89; homozygote comparison: OR = 1.21, 95% CI, 0.48-3.03; dominant model: OR = 0.86, 95% CI, 0.50-1.48, recessive model: OR = 1.21, 95% CI, 0.62-2.33, and allele comparison: OR = 1.17, 95% CI, 0.79-1.76, respectively). Apparent heterogeneity was detected. However, no evidence of publication bias was found.
conclusionsThis meta-analysis provides evidence that the ADIPOQ +45 T/G polymorphism was not related to the risk of GDM. Further multicenter, prospective studies with larger sample size would be valuable to confirm the result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.